A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 86; no. 2; pp. 207 - 212
• Main Authors: Hu, Xingsheng, Han, Baohui, Gu, Aiqin, Zhang, Yiping, Jiao, Shun Chang, Wang, Chang-li, He, Jintao, Jia, Xueke, Zhang, Li, Peng, Jiewen, Wu, Meina, Ying, Kejing, Wang, Junye, Ma, Kewei, Zhang, Shucai, You, Changxuan, Tan, Fenlai, Wang, Yinxiang, Ding, Lieming, Sun, Yan
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ireland Ltd 01.11.2014; Elsevier
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Crown Ethers - adverse effects; Crown Ethers - therapeutic use; efficacy; EGFR TKIs; Female; Hematology, Oncology and Palliative Medicine; Humans; Icotinib; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Male; Medical sciences; Middle Aged; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Mutation; Neoplasm Staging; Non-small-cell lung cancer; Phase IV; Pneumology; Pulmonary/Respiratory; Quinazolines - adverse effects; Quinazolines - therapeutic use; real-world study; Receptor, Epidermal Growth Factor - genetics; Retreatment; Retrospective Studies; Risk Factors; safety; Treatment Outcome; Tumors; Tumors of the respiratory system and mediastinum; Young Adult; World; Icotinib; EGFR TKIs; safety; Non-small-cell lung cancer; real-world study; Phase IV; efficacy; Lung cancer; Multicenter study; non-small cell lung carcinoma; Epidermal growth factor receptor; Efficiency; Phase IV trial; Bronchus disease; Advanced stage; Safety; Monitoring; Public health; Non small cell carcinoma; Lung disease; Respiratory disease; Malignant tumor; Treatment; Surveillance; Arm; Cancer

Highlights • We reported the application of icotinib in the routine clinical setting. • Favorable tolerability of icotinib was seen in overall population and elder patients. • Icotinib displayed antitumor activities in unselected patients. • More efficacy benefits were documented in EGFR-mutant pati...